A Phase 1/2 Study of VLS-1488 in People With Various Types of Cancer

Full Title

A Phase I/II Study of VLS-1488 (An Oral KIF18A Inhibitor) in Subjects with Advanced Cancer

Purpose

Researchers want to find the best dose of VLS-1488 to treat various types of advanced cancer. VLS-1488 blocks KIF18A, a protein that plays a role in the rapid growth of cancer cells. By blocking KIF18A, VLS-1488 may cause cancer cells to stop growing and die. VLS-1488 is taken orally (by mouth).

This study is for people with these cancers:

• Ovarian cancer
• Ovarian and uterine carcinosarcomas
• Uterine serous carcinoma
• Squamous cell non-small cell lung cancer
• Triple-negative breast cancer
• Gastric (stomach) cancer
• Esophageal cancer
• Colorectal cancer
• Bladder cancer
• Head and neck cancer

Who Can Join

To join this study, there are a few conditions. You must:

• Have advanced cancer that cannot be successfully treated with standard therapies.
• Have recovered from the serious side effects of prior treatments before taking VLS-1488.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information and to see if you can join this study, please call Dr. Claire Friedman’s office at 646-888-4593.